June 25 (Bloomberg) -- Bristol-Myers Squibb Co. and AstraZeneca Plc. said patients taking their experimental diabetes pill, shown effective in a two-year study, had more breast and bladder cancers than those on a standard drug.
In all the clinical programs, nine breast cancers and nine bladder cancers were seen among 5,478 patients taking the drug, dapagliflozin, compared with one breast and one bladder cancer among the 3,156 in control groups, Bristol-Myers and AstraZeneca said in a statement today. There was no imbalance in overall cancer risk, the companies said.
via businessweek.com
No comments:
Post a Comment